MONTREAL, Oct. 11, 2018 (GLOBE NEWSWIRE) -- Relevium Technologies Inc. (TSX.V: “RLV”, OTCQB: “RLLVF” and Frankfurt: “6BX”) (the “Company” or “Relevium”), announced its plans to increase its presence in Walmart.com and ramp up its current offering to over thirty (30) SKUs before the end of the year.
Following the successful initial test launch of three (3) SKUs, the Company is now ready to introduce up to thirty (30) new SKUs of its Bioganix® Gold Series formulated products before the end of this year. The Company has also begun the regulatory and compliance process to launch its formulated products in the Canadian market and plans to test walmart.ca as soon as the products obtain natural health product approvals from Health Canada.
"Following an initial market testing period, we are now expanding our presence in walmart.com to over thirty (30) SKUs and we are targeting walmart.ca platform for the initial launch of the Bioganix® Gold Series brand into the Canadian market” stated Abis Hussain, Chief Marketing Officer.
“We are working through the regulatory process to launch two (2) exclusive science based formulated products into the Canadian market and we are monitoring Walmart’s recently announced intention to explore the cannabis infused market as we see this as a potential platform for our LeefyLyfe® brand for North America” stated Aurelio Useche, Chief Executive Officer
The Company continues to make significant progress in its OTC nutraceutical formulated business and recently announced a line of hemp derived organic CBD infused products under the LeefyLyfe® brand for the European market.
About Relevium Technologies
Relevium is a publicly-traded company that operates in the health and wellness industry, a multi-billion-dollar market worldwide.
Relevium markets its products as dietary supplements, nutraceuticals, sports nutrition and nutri-cosmeceuticals. The Company plans on unveiling a complete line of dietary supplements for consumers derived from Cannabis Sativa and Cannabis Indica. The Company’s initial focus will be on creating a full spectrum extract rich in CBD (cannabidiol) which will be marketed and sold throughout North America. Relevium is also focused on developing a complete line of supplements, nutraceuticals, sports nutrition and nutri-cosmeceuticals. Relevium’s products and brands such as Bioganix® have achieved market penetration and now sold at some of the world’s largest retailers such as Walmart.com.
Relevium is also focused on the development, acquisition, marketing and sale of consumer products that are derived from cannabis and industrial hemp and other ingredients that are generally accepted as safe. The Company uses cannabinoids and ingredients that have achieved GRAS status (generally accepted as safe) to create brands that are sold via wholesale channels, retail channels and online distribution.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. All statements in this news release, other than statements of historical facts, including statements regarding future estimates, plans, objectives, assumptions or expectations of future performance, including the timing and completion of the proposed acquisitions, are forward-looking statements and contain forward-looking information. Generally, forward- looking statements and information can be identified by the use of forward-looking terminology such as "intends" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or "occur". Forward-looking statements are based on certain material assumptions and analysis made by the Company and the opinions and estimates of management as of the date of this press release, including the assumptions that the Company will be able to apply for and ultimately obtain an ACMPR licence, the proposed business of Biocannabix will develop as anticipated, that the Company will raise sufficient funds to develop the Biocannabix business, and that the Company will obtain all requisite regulatory approvals. These forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements or forward-looking information. Important factors that may cause actual results to vary, include, without limitation, the risk that the proposed business developments may not occur as planned; the timing and receipt of requisite approvals and failure to raise sufficient funds. Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward- looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.
On Behalf of the Board of Directors
RELEVIUM TECHNOLOGIES INC.
President and CEO
For more information about this press release: